Stay updated with breaking news from Its Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Issuer: Immunic, Inc. / Key word(s): Study results Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human
Issuer: Immunic, Inc. / Key word(s): Study Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease 05.05.2022 / 12:30 The issuer is solely responsible for the content of this announcement. Immunic Announces Start of Patient Cohorts in Its Phase 1 Cli...
Issuer: Immunic, Inc. / Key word(s): Study Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease 05.05.2022 / 12:30 The issuer is
Analysts called these out as a group of emerging agents that could one day supplant our existing coronavirus therapies.
Battered by the second wave of covid-19, the government recalibrates its vaccination strategy in the hope of inoculating India's 900 million adult population by December 31. How realistic is this target? - Issue Date: Jun 21, 2021